Heart failure SGLT2 inhibitors benefit heart failure patients regardless of BMI
Thelimbic,
Normal weight, overweight and obese heart failure (HF) patients see similar cardiovascular benefits with SGLT2 inhibitors…
Normal weight, overweight and obese heart failure (HF) patients see similar cardiovascular benefits with SGLT2 inhibitors…
Ένα στα τρία παιδιά, ηλικίας από 6 έως 9 χρόνων που ζουν στην Ευρώπη, είναι υπέρβαρα ή παχύσαρκα.
02-09-2022 | Diabetes | News | Article medwireNews: A flurry of publications accompanying the primary findings of DELIVER shows…
Barcelona – Der SGLT2-Inhibitor Dapagliflozin senkt das Risiko für kardiovaskulären Tod und Verschlimmerung der…